The FDA approved the Tecentriq label expansion alongside Natera’s Signatera as a companion diagnostic. More: Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod Source: fierce
read moreWith the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA. More: After Makary departure, CDER chief Tracy Beth Høeg likely headed out at FDA: report Source: fierce
read moreThe company doubled sales of its Biogen-partnered Alzheimer’s disease treatment during its 2025 fiscal year. More: Eisai's slow push toward blockbuster Leqembi sales gains steam with 0M forecast Source: fierce
read moreThe U.S. Supreme Court has issued an emergency order, temporarily blocking a federal appeals court ruling in Louisiana which would have prevented the abortion pill mifepristone from being prescribed over the phone and sent through the mail in the United
read moreDespite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportunities amid the tumult. More: Health execs persevere in new policy landscape Source:
read more© 1994 - 2026 B.M. Pharmaceuticals